Impact of Inflammatory Bowel Disease on Radical Prostatectomy Outcomes and Costs of Care

Overview

Journal Prostate Int

Date 2021 Aug 13

PMID 34386447

Citations 1

Authors

Ilana P Goldberg

Steven L Chang

Shilajit D Kundu

Benjamin I Chung

Eric A Singer

Affiliations

Soon will be listed here.

Abstract

Background: Recent studies suggest an association between prostate cancer and inflammatory bowel disease (IBD). Our objectives were to investigate clinical and financial impacts of IBD on radical prostatectomy (RP) and to determine the impact of surgical approach on our findings.

Methods: The Premier Hospital Database was queried for patients who underwent RP from 2003 to 2017. Multivariable logistic regression models were used to determine the independent impact of IBD on complications and readmission rates. We determined 90-day readmissions and examined 90-day hospital costs adjusted to 2019 US dollars with multivariable quantile regression models.

Results: Our study population included 262,189 men with prostate cancer, including 3,408 (1.3%) with IBD. There were higher odds for any complication for IBD patients compared with non-IBD controls for RP (15.64% vs. 10.66%). Patients with IBD had overall complication rates of 14.1% ( < 0.05) for open surgery and 17.2% for minimally invasive surgery (MIS) ( < 0.01). Between 2013 and 2017, the IBD cohort had significantly more complications (odds ratios (ORs): 2; 95% confidence interval (CI): 1.5 to 2.67; 0.0001), was more likely to have surgical costs in the top quartile (OR: 1.6; 95% CI: 1.23 to 2.1; < 0.01), and had higher readmission rates (OR: 1.51; 95% CI: 1.1 to 2.06; = 0.01).

Conclusions: The IBD cohort who underwent MIS had the highest complication rates. Hospital readmissions and surgical costs were significantly higher for the IBD cohort who underwent RP between 2013 and 2017, when a minimally invasive approach was more prevalent than an open approach. These findings may be important when deciding which surgical approach to take when performing RP on men with IBD.

Citing Articles

Inflammatory Bowel Disease as a Risk Factor for Complications and Revisions Following Lumbar Discectomy.

Zhang Y, Chi J, Manley B, Oh E, Yang H, Wang J Global Spine J. 2024; :21925682241270069.

PMID: 39069374 PMC: 11571289. DOI: 10.1177/21925682241270069.

References

Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T . Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol. 2010; 105(7):1480-7. DOI: 10.1038/ajg.2009.760. View

Koenigs K, McPhedran P, Spiro H . Thrombosis in inflammatory bowel disease. J Clin Gastroenterol. 1987; 9(6):627-31. View

Yadav S, Singh S, Harmsen W, Edakkanambeth Varayil J, Tremaine W, Loftus Jr E . Effect of Medications on Risk of Cancer in Patients With Inflammatory Bowel Diseases: A Population-Based Cohort Study from Olmsted County, Minnesota. Mayo Clin Proc. 2015; 90(6):738-46. PMC: 4458158. DOI: 10.1016/j.mayocp.2015.03.024. View

Ball M, Reese A, Mettee L, Pavlovich C . Safety of minimally invasive radical prostatectomy in patients with prior abdominopelvic or inguinal surgery. J Endourol. 2014; 29(2):192-7. PMC: 4313405. DOI: 10.1089/end.2014.0449. View

DHoore W, Bouckaert A, Tilquin C . Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol. 1996; 49(12):1429-33. DOI: 10.1016/s0895-4356(96)00271-5. View

Burns J, Weiner A, Catalona W, Li E, Schaeffer E, Hanauer S . Inflammatory Bowel Disease and the Risk of Prostate Cancer. Eur Urol. 2018; 75(5):846-852. PMC: 6542355. DOI: 10.1016/j.eururo.2018.11.039. View

Murphy C, Heller S, Ruth K, Buyyounouski M, Weinberg D, Uzzo R . Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with modern treatment techniques. Pract Radiat Oncol. 2014; 5(3):e215-e222. DOI: 10.1016/j.prro.2014.09.004. View

Yuh B, Kwon Y, Shinder B, Singer E, Jang T, Kim S . Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer. Prostate Int. 2019; 7(3):102-107. PMC: 6713798. DOI: 10.1016/j.prnil.2018.10.002. View

Dahlhamer J, Zammitti E, Ward B, Wheaton A, Croft J . Prevalence of Inflammatory Bowel Disease Among Adults Aged ≥18 Years - United States, 2015. MMWR Morb Mortal Wkly Rep. 2016; 65(42):1166-1169. DOI: 10.15585/mmwr.mm6542a3. View

10.

Navaneethan U, Parasa S, Venkatesh P, Ganapathi T, Kiran R, Shen B . Impact of inflammatory bowel disease on post-cholecystectomy complications and hospitalization costs: a Nationwide Inpatient Sample study. J Crohns Colitis. 2012; 7(5):e164-70. DOI: 10.1016/j.crohns.2012.07.032. View

11.

Hu J, Gandaglia G, Karakiewicz P, Nguyen P, Trinh Q, Shih Y . Comparative effectiveness of robot-assisted versus open radical prostatectomy cancer control. Eur Urol. 2014; 66(4):666-72. DOI: 10.1016/j.eururo.2014.02.015. View

12.

Biancone L, Onali S, Petruzziello C, Calabrese E, Pallone F . Cancer and immunomodulators in inflammatory bowel diseases. Inflamm Bowel Dis. 2014; 21(3):674-98. DOI: 10.1097/MIB.0000000000000243. View

13.

Kaplan G, Bernstein C, Coward S, Bitton A, Murthy S, Nguyen G . The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology. J Can Assoc Gastroenterol. 2019; 2(Suppl 1):S6-S16. PMC: 6512243. DOI: 10.1093/jcag/gwy054. View

14.

Ginzburg S, Hu F, Staff I, Tortora J, Champagne A, Salner A . Does prior abdominal surgery influence outcomes or complications of robotic-assisted laparoscopic radical prostatectomy?. Urology. 2010; 76(5):1125-9. DOI: 10.1016/j.urology.2010.03.039. View

15.

Ilic D, Evans S, Allan C, Jung J, Murphy D, Frydenberg M . Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer. Cochrane Database Syst Rev. 2017; 9:CD009625. PMC: 6486168. DOI: 10.1002/14651858.CD009625.pub2. View

16.

Ge Y, Shi Q, Yao W, Cheng Y, Ma G . The association between inflammatory bowel disease and prostate cancer risk: a meta-analysis. Prostate Cancer Prostatic Dis. 2019; 23(1):53-58. DOI: 10.1038/s41391-019-0177-7. View

17.

Bazerbachi F, Sawas T, Vargas E, Haffar S, Deepak P, Kisiel J . Bariatric Surgery Is Acceptably Safe in Obese Inflammatory Bowel Disease Patients: Analysis of the Nationwide Inpatient Sample. Obes Surg. 2017; 28(4):1007-1014. DOI: 10.1007/s11695-017-2955-4. View

18.

Nguyen G, Tuskey A, Dassopoulos T, Harris M, Brant S . Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis. 2007; 13(12):1529-35. DOI: 10.1002/ibd.20250. View

19.

Leow J, Reese S, Jiang W, Lipsitz S, Bellmunt J, Trinh Q . Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States. Eur Urol. 2014; 66(3):569-76. DOI: 10.1016/j.eururo.2014.01.029. View

20.

Wagner C, Srougi V, Sanchez-Salas R . Getting ready for the first robotic prostatectomy, from basics to real practice. Curr Opin Urol. 2017; 27(4):323-329. DOI: 10.1097/MOU.0000000000000409. View